Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

23%

3 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
6(46.2%)
Phase 2
4(30.8%)
Phase 3
3(23.1%)
13Total
Phase 1(6)
Phase 2(4)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT06588738Phase 3Completed

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

Role: lead

NCT06586112Phase 3Completed

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

Role: lead

NCT06846541Phase 3Active Not Recruiting

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

Role: lead

NCT05966480Phase 2Active Not Recruiting

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Role: lead

NCT05739435Phase 2Active Not Recruiting

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

Role: lead

NCT07442149Phase 1Completed

An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005

Role: lead

NCT07378579Phase 1Completed

An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001

Role: lead

NCT06962774Phase 1Completed

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

Role: lead

NCT05600036Phase 2Completed

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Role: lead

NCT06952634Phase 1Recruiting

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

Role: lead

NCT05953688Phase 2Terminated

POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU

Role: lead

NCT05330858Phase 1Completed

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

Role: lead

NCT05431634Phase 1Completed

Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

Role: lead

All 13 trials loaded